Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses: 2023-2025

Historic Other Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Mar 2025 value amounting to $4.4 million.

  • Monte Rosa Therapeutics' Other Accumulated Expenses rose 104.68% to $4.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $4.4 million, marking a year-over-year increase of 104.68%. This contributed to the annual value of $3.4 million for FY2024, which is 100.72% up from last year.
  • As of Q1 2025, Monte Rosa Therapeutics' Other Accumulated Expenses stood at $4.4 million, which was up 31.81% from $3.4 million recorded in Q4 2024.
  • Monte Rosa Therapeutics' Other Accumulated Expenses' 5-year high stood at $4.4 million during Q1 2025, with a 5-year trough of $1.3 million in Q3 2024.
  • Its 3-year average for Other Accumulated Expenses is $2.7 million, with a median of $2.5 million in 2023.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Other Accumulated Expenses crashed by 55.19% in 2024, and later soared by 104.68% in 2025.
  • Over the past 3 years, Monte Rosa Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.7 million in 2023, then skyrocketed by 100.72% to $3.4 million in 2024, then soared by 104.68% to $4.4 million in 2025.
  • Its Other Accumulated Expenses was $4.4 million in Q1 2025, compared to $3.4 million in Q4 2024 and $1.3 million in Q3 2024.